Financial Performance - Total revenue for Q4 fiscal 2026 was $127.1 million, representing a 16% year-over-year increase[7] - Fiscal year 2026 total revenue reached $480.6 million, a 14% increase year-over-year[7] - Adjusted EBITDA for Q4 was $29.4 million, compared to $16.4 million in the same period last year[7] - Net income for the three months ended January 31, 2026, was $1,295,000, compared to a net loss of $6,390,000 in the same period of 2025[31] - The company achieved a net income of $2.3 million for fiscal 2026, compared to a net loss of $58.5 million in fiscal 2025[7] - Adjusted EBITDA for the three months ended January 31, 2026, was $29,419 thousand, compared to $16,373 thousand for the same period in 2025, reflecting a year-over-year increase of 80.0%[42] - Free cash flow for the fiscal year ended January 31, 2026, was $54,417,000, significantly up from $8,292,000 in 2025, indicating a substantial improvement in cash generation[46] Client Metrics - Average number of healthcare services clients (AHSCs) was 4,658 in Q4, up 7% year-over-year[7] - Average number of healthcare services clients (AHSCs) increased to 4,658 in the three months ended January 31, 2026, from 4,341 in the same period of 2025, reflecting a growth of 7.3%[50] - Total revenue per AHSC rose to $27,279 in the three months ended January 31, 2026, compared to $25,266 in the same period of 2025, marking an increase of 8.0%[50] Revenue Breakdown - Subscription and related services revenue rose to $55,924,000, a 7.3% increase from $51,793,000 year-over-year[29] - Payment solutions revenue grew significantly to $35,720,000, up 44.7% from $24,676,000 in the prior year[29] - Patient payment volume for the fiscal year ended January 31, 2026, reached $4,873 million, up from $4,420 million in 2025, representing an increase of 10.2%[52] - Payment facilitator volume percentage improved to 84% for the three months ended January 31, 2026, compared to 82% in the same period of 2025, indicating a positive trend in payment processing operations[52] Expenses and Losses - Total expenses for the three months ended January 31, 2026, were $132,624,000, an increase of 13.0% compared to $117,293,000 in the same period of 2025[29] - The operating loss for the three months ended January 31, 2026, was $5,557,000, an improvement from a loss of $7,612,000 in the same period of 2025[29] - GAAP operating expenses for the three months ended January 31, 2026, totaled $101,538,000, an increase from $93,411,000 in the same period of 2025, reflecting a rise of 8.5%[48] - General and administrative expenses for the three months ended January 31, 2026, increased to $26,965,000 from $18,415,000 in the same period of 2025, a significant rise of 46.4%[48] - Research and development expenses for the fiscal year ended January 31, 2026, were $121,481,000, compared to $117,364,000 in 2025, showing a growth of 3.6%[48] Cash Flow and Investments - Cash, cash equivalents, and restricted cash as of January 31, 2026, was $73.8 million, down from $84.2 million a year earlier[7] - Net cash provided by operating activities for the three months ended January 31, 2026, was $33,662 thousand, up from $16,256 thousand in the prior year, representing a growth of 107.0%[33] - The company reported a net cash used in investing activities of $(142,619) thousand for the three months ended January 31, 2026, compared to $(7,058) thousand in the same period of 2025[33] - The company incurred stock-based compensation expense of $18,038 thousand for the three months ended January 31, 2026, slightly up from $17,162 thousand in the same period of 2025[42] - The company’s deferred revenue increased to $11,343 thousand for the three months ended January 31, 2026, compared to $10,490 thousand in the same period of 2025, reflecting a growth of 8.2%[33] Acquisition and Market Expansion - The AccessOne acquisition was completed for approximately $164 million, expanding the addressable market for healthcare payments[8] - The company completed the AccessOne Acquisition on November 12, 2025, expanding its payment solutions offerings[29] - The company expects approximately $37 million contribution from AccessOne in fiscal 2027[14] - Fiscal 2027 revenue outlook is lowered to a range of $510 million to $520 million, down from a previous range of $545 million to $559 million[14] - Adjusted EBITDA outlook for fiscal 2027 is maintained at a range of $125 million to $135 million[15]

Market Overview - In fiscal year 2026, the platform facilitated approximately 180 million patient visits, representing about one in six ambulatory patient visits in the United States[24]. - The total addressable market is estimated at approximately $24 billion, including $6.3 billion from subscription services, $9.1 billion from payment processing fees, and $8.2 billion from Network solutions revenue[34]. - The company anticipates continued growth driven by trends such as increased adoption of digital solutions and the transition to value-based care models[34]. Revenue Streams - Revenue is generated through three streams: subscription services, payment solutions, and Network Solutions, with a focus on recurring revenue from subscription fees[26]. - The business model provides visibility into future revenue, primarily derived from recurring subscription and payment processing fees[27]. Acquisitions and Growth - The company completed the AccessOne Acquisition, expanding its addressable market for healthcare payments and enhancing cash flow for healthcare providers[25]. Competition and Market Position - The company faces competition from both established vendors and new entrants incorporating AI into healthcare technology solutions[42]. Employee and Organizational Structure - As of January 31, 2026, the company had 1,789 full-time employees, with 756 in the United States and 1,033 internationally[66]. - The company has 502 employees in sales and marketing, 542 in research and development, 551 in services and support, and 194 in general and administrative roles[66]. - The company has not experienced any work stoppages and considers its relationship with employees to be good[66]. - The company emphasizes an inclusive workplace, supporting gender equality and professional development for employees of all backgrounds[67]. - The company has operated as a fully remote organization since 2020, enhancing access to top talent and flexibility for employees[68]. Compliance and Regulatory Environment - The company is subject to various federal and state laws regarding privacy and data protection, including the California Consumer Privacy Act (CCPA) and the Health Insurance Portability and Accountability Act (HIPAA)[50][52]. - The company must comply with extensive consumer protection and fair lending laws through its subsidiary, AccessOne MedCard, which offers medical financing products[61]. - The company is subject to the Federal Acquisition Regulation (FAR) as a federal government contractor, which includes compliance and reporting requirements[56]. - The company faces potential penalties for violations of healthcare regulations, including the Anti-Kickback Statute and the False Claims Act[57][58]. - The company must adhere to financial services laws, including the U.S. Bank Secrecy Act and anti-money laundering regulations[60]. - The company regularly reviews its privacy program in light of Federal Trade Commission (FTC) guidance and enforcement actions[48]. - The company is exposed to evolving state and federal privacy laws, which may increase compliance complexity and costs[52]. Financial Overview - As of January 31, 2026, the company had a principal balance of $90.0 million outstanding on the Bridge Loan, with an interest rate of three-month SOFR plus a margin of 4.0% per annum[414]. - The company completed refinancing on March 13, 2026, repaying all outstanding obligations under the Bridge Loan using a new 5-year $275.0 million senior secured revolving credit facility[414]. - For the fiscal year ended January 31, 2026, approximately 84% of the company's expenses were denominated in U.S. Dollars[417]. - Foreign currency gains and losses for the fiscal year ended January 31, 2026, included gains of $0.2 million and losses of $0.4 million for the years ended January 31, 2026 and 2025, respectively[418]. - The company entered into foreign currency forward contracts to hedge a portion of its Canadian Dollar denominated payroll payments, with 90% designated as a cash flow hedge[419]. - A 1% increase or decrease in foreign exchange rates between the Canadian Dollar, Indian Rupee, and U.S. Dollar is not expected to have a material effect on the company's results of operations or financial condition[420]. Technology and Innovation - The company integrates artificial intelligence into its solutions to enhance automation, personalization, and operational efficiency[36]. - Privacy and security are prioritized, with comprehensive measures in place to safeguard client data and compliance with industry standards[37]. Recognition and Awards - The company was recognized in multiple awards, including being named to the 2025 Deloitte Technology Fast 500 and TIME's 2025 World's Top HealthTech Companies list[67]. Investment Strategy - The company maintains a commitment to preserving principal while maximizing income through its investment activities, focusing on cash equivalents with short maturities[413].

Financial Performance - Phreesia reported fourth-quarter earnings of 2 cents, missing the consensus estimate of 7 cents [1] - Sales reached $127.07 million, up 16% year-over-year, beating the consensus of $126.62 million [1] - The average number of healthcare service clients (AHSCs) was 4,658 in the quarter, reflecting a 7% year-over-year increase [1] Fiscal Guidance - The company lowered its fiscal 2027 revenue outlook to $510–$520 million, down from a previous range of $545–$559 million, due to reduced visibility into pharma client spending and weaker-than-expected commitments for the second half of the year [2] Key Milestones - CEO Chaim Indig highlighted several financial milestones, including achieving positive GAAP net income of $2.3 million, crossing $100 million in Adjusted EBITDA, and generating $50 million in free cash flow for fiscal year 2026 [3] - Phreesia shares experienced a significant decline of 28.6%, dropping to $8.14 in pre-market trading following the earnings announcement [3]

Market Overview - The U.S. stock market is set for a strong opening on March 31, 2026, with major index futures showing significant gains, indicating a bullish sentiment as the first quarter concludes [1] - S&P Futures are trading at 6460.25, up 72.00 points (1.13%), Nasdaq Futures at 23402.25, up 262.50 points (1.13%), and Dow Futures at 45971.00, up 506.00 points (1.11%) [2] Sector Performance - The energy sector is leading with the United States Oil Fund (USO) up 4.53%, indicating strong bullish momentum [3] - Financials are also performing well, with the Financial Select Sector SPDR Fund (XLF) up 1.15%, showing bullish divergence despite recent pressures [3] - Conversely, the Semiconductor ETF (SMH) is down 3.93%, the Solar Power ETF (TAN) is down 2.99%, and the Cannabis ETF (MSOS) is down 3.96%, indicating a rotation out of growth-sensitive sectors [4] Major Stock Movements - Apellis Pharmaceuticals Inc. (APLS) has surged 135.5% to $40.25 on high volume, driven by significant corporate developments [5] - Classover Holdings Inc. (KIDZ) is up 64.6%, and Centessa Pharmaceuticals plc (CNTA) has risen 45.6% to $40.15 [5] - On the downside, PepGen Inc. (PEPG) has dropped 52.0% to $2.03, and Phreesia Inc. (PHR) is down 26.4% to $8.40 following recent updates [6] Upcoming Earnings - McCormick & Company Incorporated (MKC) reported Q1 2026 results with an estimated EPS of $0.61, along with early reporters TD SYNNEX Corporation (SNX) and FactSet Research Systems Inc. (FDS) [8] - Nike Inc. (NKE) is set to release its Q3 2026 earnings after the market close, with analysts expecting an EPS of $0.29, which will be crucial for the retail sector [9] - ConAgra Brands Inc. (CAG) and Cal-Maine Foods Inc. (CALM) are scheduled to report before the market opens on April 1 [10]

Phreesia Sees Weaker Pharma Spending VisibilityPhreesia on Monday lowered its fiscal 2027 revenue outlook to $510–$520 million, down from $545–$559 million, citing reduced visibility into pharma client spending and weaker-than-expected commitments for the second half of the year.Some clients are allocating fewer dollars due to brand-specific factors, including regulatory impacts.Management does not view this as a structural demand shift but flagged increased variability in network solutions revenue, particu ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Revenue Growth: Phreesia's total revenue for Q4 reached $127.1 million, a 16% year-over-year increase, surpassing estimates.Operational Efficiency: The company achieved a positive GAAP net income of $2.3 million and generated $50 million in free cash flow.Financial Stability: With a quick and current ratio of 2.44 and a debt-to-equity ratio of 0.01, Phreesia maintains strong liquidity and low leverage.(NYSE:PHR) is a healthcare technology company that provides patient intake management solutions. It helps h ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Data and Key Metrics Changes - For Q4 fiscal year 2026, revenue was $127.1 million, up 16% year-over-year, with growth led by Payment Solutions following the acquisition of AccessOne [14] - Adjusted EBITDA was $29.4 million, compared to $16.4 million in the same period last year, representing an Adjusted EBITDA margin of 23% [14] - Free cash flow was $28.5 million, up $19.3 million year-over-year, marking the strongest quarterly free cash flow to date [16] - Cash and cash equivalents as of January 31, 2026, were $73.8 million compared to $84.2 million at January 31, 2025 [16] Business Line Data and Key Metrics Changes - Average Healthcare Services Clients (AHSCs) reached 4,658, an increase of 138 from the prior quarter, with 80 of these contributed through the AccessOne acquisition [14] - Fourth quarter total revenue per AHSC was $27,279, up 8% year-over-year [14] Market Data and Key Metrics Changes - The healthcare industry is facing challenges including FDA guidelines, insurance coverage, patient utilization, and provider reimbursement, impacting visibility into spending commitments from pharmaceutical manufacturers [10][11] - Specific areas such as vaccines and public health have seen reduced spending, affecting revenue forecasts [25][61] Company Strategy and Development Direction - The company aims to position AccessOne for growth and scale its HCP marketing offering while continuing to integrate AI into its operations [13][12] - The emphasis is on building products that address access, affordability, and outcomes, with a focus on financial services and patient engagement [11] - The company is maintaining its Adjusted EBITDA outlook of $125 million-$135 million for fiscal year 2027 despite lowering revenue expectations, reflecting operational leverage and efficiency gains [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a tough market environment but believes the underlying demand for Phreesia's offerings remains strong [10][11] - The company is experiencing shorter visibility into spending commitments, particularly in the Network Solutions business, but does not view this as a structural shift in demand [18] - Management is confident in the company's financial profile and ability to pursue growth opportunities while absorbing challenges [12][13] Other Important Information - The company completed a refinancing of its bridge loan, replacing it with a new five-year, $275 million senior secured revolving credit facility [17] - The company is prioritizing capital allocation to enhance long-term shareholder value, including potential share repurchases [17] Q&A Session Summary Question: Dynamics in the Network Solutions end market and guidance change - Management indicated that the visibility into client spending is fluid and not broad-based, affecting specific brands and therapeutic areas [24][25] Question: ProviderConnect's contribution to HCP marketing - Management stated that ProviderConnect is still in early stages and its impact on revenue outlook is minimal at this time [30] Question: Impact of price negotiations on pharma clients' budgeting - Management clarified that current issues are more related to specific therapeutic areas and regulatory activity rather than price negotiations [33] Question: Cost actions impacting EBITDA guidance - Management emphasized ongoing efficiency improvements and AI-driven operational enhancements as key to maintaining EBITDA guidance despite revenue reductions [36][37] Question: AI's impact on competitive landscape - Management believes AI capabilities will enhance the breadth of offerings and provide significant value to clients [55] Question: Visibility into Network Solutions revenue - Management noted that the lack of visibility primarily affects the second half of the fiscal year, with Q1 showing better-than-expected performance [86]

Financial Data and Key Metrics Changes - For Q4 fiscal year 2026, revenue was $127.1 million, up 16% year-over-year, with growth led by Payment Solutions following the acquisition of AccessOne [14] - Adjusted EBITDA was $29.4 million, compared to $16.4 million in the same period last year, representing an adjusted EBITDA margin of 23% [14] - Free cash flow was $28.5 million, up $19.3 million year-over-year, marking the strongest quarterly free cash flow to date [16] - The company achieved positive GAAP net income for the first time in its history as a publicly traded company [8] Business Line Data and Key Metrics Changes - Average Healthcare Services clients (AHSCs) reached 4,658, an increase of 138 from the prior quarter, with 80 of these contributed through the AccessOne acquisition [14] - Total revenue per AHSC was $27,279, up 8% year-over-year [14] Market Data and Key Metrics Changes - The healthcare industry is facing challenges including FDA guidelines, insurance coverage, patient utilization, and provider reimbursement [10] - There is variability in financial forecasts due to shorter visibility into spending commitments from certain pharmaceutical manufacturers in the Network Solutions business [11] Company Strategy and Development Direction - The company is focusing on growth initiatives such as provider financing and HCP marketing, with the acquisition of AccessOne being central to its strategy [9] - The launch of ProviderConnect is aimed at enhancing healthcare provider marketing, leveraging the existing PatientConnect platform [9] - The company is committed to building products that address access, affordability, and outcomes, with a focus on financial services and patient engagement [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a tough market environment but believes the company is well-positioned to grow on its own terms [10] - The company is lowering its revenue outlook for fiscal year 2027 to a range of $510 million-$520 million, down from a prior range of $545 million-$559 million, due to reduced visibility into spending commitments [18] - Adjusted EBITDA outlook for fiscal year 2027 remains unchanged at $125 million-$135 million, reflecting operational leverage and efficiency gains [19] Other Important Information - The company completed a refinancing of its bridge loan, replacing it with a new senior secured revolving credit facility [17] - Cash and cash equivalents as of January 31, 2026, were $73.8 million, down from $84.2 million a year earlier [16] Q&A Session Summary Question: Dynamics in the Network Solutions end market and guidance change - Management indicated that the lack of visibility is not broad-based but specific to certain brands and therapeutic areas, such as vaccines and public health [24][25] Question: ProviderConnect's contribution to HCP marketing - Management stated that ProviderConnect is still in early stages and its impact on revenue outlook is minimal at this time [30] Question: Impact of price negotiations on pharma clients' budgeting - Management clarified that current issues are more related to specific therapeutic areas and regulatory activities rather than price negotiations [33] Question: Cost actions impacting EBITDA guidance - Management emphasized ongoing capital investment and efficiency improvements as key factors supporting the unchanged EBITDA outlook [36] Question: AI's role in competitive landscape - Management believes AI will enhance the breadth of offerings and improve operational efficiencies, positioning the company favorably in the market [55] Question: Visibility into Network Solutions revenue - Management noted that the recent updates pertain primarily to PatientConnect, with positive developments in ProviderConnect [65] Question: GLP-1 drugs impact on Network Solutions - Management categorized GLP-1 drugs as part of the challenges affecting revenue forecasts, similar to vaccines and public health issues [62] Question: Strategy for scaling AccessOne - Management indicated that growth will involve both expanding within existing competencies and exploring new opportunities in the healthcare provider ecosystem [72]